Nanobiotix CEO Dr. Laurent Lévy is elected
co-president of the French Technology Platform on Nanomedicine (FTPN)
Podcast available at www.medtechmatters.com
PARIS (Business Wire EON/PRWEB ) June 4, 2008 --
Nanobiotix,
an emerging nanomedicine company focused on cancer therapy, announced
today that its chief executive officer, Laurent
Lévy, Ph.D., has been elected as
co-president of the French Technology Platform on Nanomedicine (FTPN),
effective immediately.
FTPN organizes communication, collaborative work and meetings among the
French-based nanomedicine community’s
stakeholders—such as companies, research
institutes, universities, hospitals, and patient associations—with
representatives from ministries, regional clusters, government agencies
and research foundations.
“I am honored to serve as the co-president of
FTPN,” said Dr. Lévy.
“FTPN’s mission is
to help accelerate the development of nanomedicine into clinical
practice for the benefit of patients. Moving forward, this evolving
field of nanomedicine will be a great challenge, one that our committed
board members are ready to undertake.”
FTPN is the counterpart to the European Technology Platform on
Nanomedicine (ETPN) and works to ensure French-based participation
in European collaborative projects. Led by market needs and industrial
developments, FTPN has the following goals: (1) identify and represent
stakeholders; (2) support industrial R&D priorities and initiatives with
a strong link and collaborative work with public-focused research; (3)
allow emergence of innovative projects in accordance with national and
local initiatives; (4) inform, and initiate dialogue with, patient
associations and the general public; and (5) link and promote work
between regulatory agencies and nanomedicine stakeholders. FTPN’s
board of directors includes—co-presidents: Dr.
Lévy and Gérard
Mathis, CSO, Cis-Bio; Patrice Marche representing INSERM and
CNRS and Jean-Pierre Benoit representing clinical research; Patrick
Boisseau, Executive Board member of the European Technology Platform
on Nanomedicine; and, Pierre-Noël Lirsac,
French representative to the European Technology Platform Nanomedicine
Mirror Group1.
Nanomedicine2 is the application
of nanotechnology to achieve breakthroughs in healthcare. It exploits
the improved and often novel physical, chemical and biological
properties of materials at the nanometer scale. Nanomedicine has the
potential to enable early detection and prevention and to essentially
improve diagnosis, treatment and follow-up of diseases.
1 Official representative from states member
and associated states member from EU.
2 Source: ETPN,
Strategic Research Agenda, November 2006.
ABOUT NANOBIOTIX
Nanobiotix is an emerging nanomedicine company combining dramatic
advances in nanotechnology and molecular biology to develop nanoXray™—
a technology platform that is expected to be turned ‘on’
and ‘off’
outside the body to selectively treat a variety of cancers safely and
noninvasively. Use of nanoXray is intended to resolve radiation
therapy’s biggest drawback: destruction of
healthy tissue and its subsequent deleterious side effects when a high
dose of Xray is necessary. The core of a nanoXray nanoparticle is
an inactive and inert substance—not a drug—that
can be activated to locally (intratumor) increase the dose of Xray,
which is then expected to lead to higher efficiency. After nanoXray
nanoparticles accumulate in the target tissues, a standard X-ray is
applied that is intended to generate a local therapeutic effect,
designed to destroy only the targeted tumor cells. This mechanism
suggests total control of the intended therapeutic effect.
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/VGhpci1IYWxmLUZhbHUtUGlnZy1Qcm9mLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.